文献速递乳腺癌

氟唑帕利联合或不联合阿帕替尼治疗gBRCA1/2突变HER2阴性转移性乳腺癌:FABULOUS研究中期分析

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

FABULOUS是一项在中国40个中心开展的多中心、三臂、开放标签、随机3期试验,评估氟唑帕利联合或不联合阿帕替尼对比化疗用于gBRCA1/2突变HER2阴性转移性乳腺癌的疗效与安全性。

要点

  • 联合组最常见3-4级治疗相关不良事件为中性粒细胞减少(13%)和高血压(13%)。

核心结论

  • 氟唑帕利联合或不联合阿帕替尼均较化疗显著改善gBRCA1/2突变HER2阴性转移性乳腺癌患者的PFS。
  • 联合阿帕替尼较氟唑帕利单药进一步显著延长PFS。

研究设计与样本

  • FABULOUS为多中心、三臂、开放标签、随机3期试验,在中国40个中心开展。
  • 纳入18-75岁女性,HER2阴性转移性乳腺癌,携带胚系BRCA1/2有害或疑似有害突变,ECOG PS 0-1。
  • 按1:1:1随机分配至氟唑帕利100mg bid联合阿帕替尼500mg qd组(n=70)、氟唑帕利150mg bid组(n=67)或化疗组(n=66)。
  • 化疗为卡培他滨1000-1250mg/m2 bid(每21天周期第1-14天)或长春瑞滨25-30mg/m2(每21天周期第1、8天)静脉注射。
  • 主要终点为盲态独立中心审查(BICR)评估的PFS,本次为预设中期分析。

关键数值与推荐

  • 联合组最常见3-4级治疗相关不良事件为中性粒细胞计数减少(9例,13%)和高血压(9例,13%)。
  • 单药组最常见3-4级治疗相关不良事件为贫血(25例,37%)和中性粒细胞计数减少(14例,21%)。
  • 化疗组最常见3-4级治疗相关不良事件为中性粒细胞计数减少(14例,24%)和白细胞计数减少(11例,19%)。
  • 严重治疗相关不良事件发生率:联合组13%、单药组18%、化疗组14%。
  • 联合组和化疗组无治疗相关死亡,单药组有1例(1%)治疗相关不良事件死亡(感染性休克)。

临床怎么用

  • 对于gBRCA1/2突变HER2阴性转移性乳腺癌患者,氟唑帕利联合阿帕替尼或氟唑帕利单药均可作为化疗的替代选择。
  • 联合方案需关注中性粒细胞减少和高血压等3-4级不良事件。
  • 单药方案需重点监测贫血和中性粒细胞减少。

局限性

  • 本次为预设中期分析,长期疗效和安全性数据尚未成熟。
  • 研究为开放标签设计。
  • 研究仅在中国开展,入组患者以汉族为主(191例,94%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Addition of anti-angiogenic inhibitors has the potential to enhance the efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors; however, clinical evidence for their use in breast cancer is scarce. The FABULOUS study assessed fuzuloparib (an oral PARP inhibitor) with or without apatinib (an oral angiogenesis inhibitor) for breast cancer. METHODS: FABULOUS was an open-label, randomised, phase 3 trial done at 40 sites in China. Eligible patients were women aged 18-75 years, with HER2-negative metastatic breast cancer with deleterious or suspected deleterious germline BRCA1 or BRCA2 (BRCA1/2) mutations and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1:1) to receive oral fuzuloparib 100 mg twice daily plus oral apatinib 500 mg once daily, oral fuzuloparib 150 mg twice daily, or chemotherapy of the physician's choice (either oral capecitabine 1000-1250 mg/m2 twice daily on days 1-14 of each 21-day cycle or intravenous vinorelbine 25-30 mg/m2 on days 1 and 8 of each 21-day cycle). Randomisation was done via a centralised interactive web-response system using block randomisation (block size of six), stratified by the number of previous chemotherapy regimens for metastatic disease, hormone receptor status, and previous use of platinum-based therapy. The primary endpoint was progression-free survival per blinded independent central review (BICR). Herein, we reported the findings of prespecified interim analysis. Efficacy was assessed in the intention-to-treat population. Safety was analysed in patients who received at least one dose of study medication. This study is registered with ClinicalTrials.gov (NCT04296370). Recruitment and follow-up are ongoing to achieve the target sample size and obtain long-term efficacy and safety data. FINDINGS: Between Oct 12, 2020, and Dec 13, 2023, 203 eligible patients were enrolled and assigned to receive fuzuloparib-apatinib (n=70), fuzuloparib (n=67), or chemotherapy (n=66). 191 (94%) patients were Han Chinese, and 12 (6%) were other ethnicity Chinese. At the present interim analysis, median time from randomisation to cutoff date was 24·2 months (IQR 13·2-31·8). Median progression-free survival per BICR was 11·0 months (95% CI 8·4-13·1) with fuzuloparib-apatinib, 6·7 months (4·2-7·6) with fuzuloparib, and 3·0 months (1·6-5·3) with chemotherapy. Compared with chemotherapy, fuzuloparib-apatinib (HR 0·27 [95% CI 0·17-0·43]; one-sided p<0·0001) or fuzuloparib alone (0·49 [0·32-0·75]; p=0·0004]) groups had significantly longer progression-free survival. Additionally, the fuzuloparib-apatinib group had significantly longer progression-free survival than fuzuloparib (0·60 [0·40-0·91]; p=0·0079). The most common grade 3-4 treatment-related adverse events were decreased neutrophil count (nine [13%]) and hypertension (nine [13%]) in the fuzuloparib-apatinib group; anaemia (25 [37%]) and decreased neutrophil count (14 [21%]) in the fuzuloparib group; and decreased neutrophil count (14 [24%]) and decreased white blood cell count (11 [19%]) in the chemotherapy group. Serious treatment-related adverse events occurred in nine (13%), 12 (18%), and eight (14%) patients in the fuzuloparib-apatinib, fuzuloparib, and chemotherapy groups, respectively. There were no treatment-related deaths in the fuzuloparib-apatinib and chemotherapy groups, and one (1%) patient in the fuzuloparib group died due to a treatment-related adverse event (septic shock). INTERPRETATION: Fuzuloparib, either as monotherapy or in combination with apatinib, provided statistically significant improvements in progression-free survival compared with chemotherapy in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations, presenting as new treatment options. FUNDING: Jiangsu Hengrui Pharmaceuticals, Natural Science Foundation of China, National Key Research and Development Program of China, Guangdong Science and Technology Department, Science and Technology Program of Guangzhou, Bureau of Science and Technology of Guangzhou, and Program for Guangdong Introducing Innovative and Entrepreneurial Teams.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Li H, Liu J, Ouyang Q, et al. Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. Lancet Oncol. 2025. PMID: 41308673. doi:10.1016/S1470-2045(25)00523-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。